Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.

Tatyana Feldman,Denise Zou,Mayvis Rebeira,Joseph G. L. Lee,Mack Harris,Wenkang Ma,Michelle A. Fanale,Thomas Manley,Joseph Feliciano,Shangbang Rao,Anuraag Kansal

Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.

2019

Tatyana Feldman
Denise Zou
Mayvis Rebeira
Joseph G. L. Lee
Mack Harris
Wenkang Ma
Michelle A. Fanale
Thomas Manley
Joseph Feliciano
Shangbang Rao
Anuraag Kansal

e19060Background: The most common frontline treatment for peripheral T-cell lymphoma (PTCL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen. In the recen...

Keywords:

Pathology
Peripheral T-cell lymphoma
Oncology
Lymphoma
Vincristine
Regimen
CHOP
Brentuximab vedotin
Medicine
Chemotherapy
Internal medicine
Cyclophosphamide
cost effectiveness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations